Takeda Pharmaceutical Co Ltd - Company Profile
Powered by
All the data and insights you need on Takeda Pharmaceutical Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Takeda Pharmaceutical Co Ltd Strategy Report
- Understand Takeda Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Takeda Pharmaceutical Co Ltd (Takeda) is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of drugs. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
Takeda Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Therapy Areas: | Actos |
Oncology | Blopress |
Gastroenterology | Takepron |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, the company along with Astellas Pharma Inc and Sumitomo Mitsui Banking Corporation entered into an agreement to establish a joint venture company. |
2024 | Others | In March, the company launched the In Their Shoes initiative to Johannesburg, South Africa. |
2024 | Contracts/Agreements | In February, the company entered into a partnership with Biological E. Limited for the production of Takeda's dengue vaccine, TAK-003. |
Competitor Comparison
Key Parameters | Takeda Pharmaceutical Co Ltd | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
---|---|---|---|---|---|
Headquarters | Japan | Switzerland | United States of America | United States of America | United States of America |
City | Chuo-Ku | Basel | Kenilworth | New York | North Chicago |
State/Province | Tokyo | - | New Jersey | New York | Illinois |
No. of Employees | 49,095 | 103,605 | 72,000 | 88,000 | 50,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Christophe Weber | Chief Executive Officer; President; Director | Executive Board | 2015 | 57 |
Milano Furuta | Chief Financial Officer | Senior Management | 2024 | - |
Mwana Lugogo | Chief Ethics & Compliance Officer | Senior Management | 2019 | 53 |
Lauren Duprey | Chief Human Resources Officer | Senior Management | 2021 | 39 |
Takako Ohyabu | Chief Global Corporate Affairs Officer | Senior Management | 2019 | 44 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer